Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail
-

Division of Anesthesia, Analgesia, and Addiction Products (DAAAP)

 

Division Director: Bob A. Rappaport, M.D. 
Deputy Directors: Sharon Hertz, M.D., and Rigoberto Roca, M.D. 
Deputy Director for Safety: Judith Racoosin, M.D., M.P.H 
Associate Director for Special Projects: Allison Lin, Ph.D., Pharm.D. 
Chiefs, Project Management Staff: Parinda Jani and Sara Stradley 
Safety Regulatory Project Manager: Katherine Won, Pharm. D.
 
The Division of Anesthesia, Analgesia, and Addiction Products regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for prescription drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:
 
  • Acute Pain, e.g.:
    • Surgical and procedural pain
    • Pain due to trauma/injury
    • Pain due to acute inflammatory processes
 
  • Chronic pain, e.g.:
    • Cancer pain
    • Neuropathic pain
    • Fibromyalgia
    • Osteoarthritis Pain
    • Low back pain
 
  • Addiction, e.g.:
    • Nicotine
    • Alcohol
    • Stimulants
    • Opioids
 
DAAAP also regulates the drug product classes that are used in surgical, procedural or ICU settings to provide patient comfort and/or ease of treatment, e.g.:
 
  • General anesthetics
  • Local anesthetics
  • Dental anesthetics
  • Topical anesthetics
  • Neuromuscular-blocking agents and neuromuscular-blocker reversal agents
 
 
 
 
Mailing Address:
 
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthesia, Analgesia, and Addiction Products
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2280
Fax: (301) 796-9723
 

 

-
-